Vascular endothelial growth factor 2

Details Vascular endothelial growth factor 2 Vascular endothelial growth factor 2

2007-04-03

2010-12-14

Huynh, Phuong (Department: 1644)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

C424S135100, C424S141100, C424S142100, C424S145100, C424S178100, C424S179100, C424S181100, C424S183100, C424S192100, C435S070210, C435S326000, C435S810000, C530S387100, C530S388100, C530S388150, C530S388230, C530S391100, C530S391300, C530S391700

Reexamination Certificate

active

07850963

ABSTRACT:
Disclosed are human VEGF-2 antibodies, antibody fragments, or variants thereof. Also provided are processes for producing such antibodies. The present invention relates to methods and compositions for preventing, treating or ameliorating a disease or disorder comprising administering to an animal, preferably a human, an effective amount of one or more VEGF-2 antibodies or fragments or variants thereof.

REFERENCES:
patent: 5073492 (1991-12-01), Chen et al.
patent: 5194596 (1993-03-01), Tischer et al.
patent: 5219739 (1993-06-01), Tischer et al.
patent: 5234908 (1993-08-01), Szabo et al.
patent: 5240848 (1993-08-01), Keck et al.
patent: 5283354 (1994-02-01), Lemischka
patent: 5326695 (1994-07-01), Andersson et al.
patent: 5607918 (1997-03-01), Eriksson et al.
patent: 5633147 (1997-05-01), Meissner et al.
patent: 5652225 (1997-07-01), Isner
patent: 5661133 (1997-08-01), Leiden et al.
patent: 5693622 (1997-12-01), Wolff et al.
patent: 5776755 (1998-07-01), Alitalo et al.
patent: 5792453 (1998-08-01), Hammond et al.
patent: 5840693 (1998-11-01), Eriksson et al.
patent: 5861301 (1999-01-01), Terman et al.
patent: 5930540 (1999-07-01), Balling
patent: 5932540 (1999-08-01), Hu et al.
patent: 5935820 (1999-08-01), Hu et al.
patent: 6040157 (2000-03-01), Hu et al.
patent: 6121246 (2000-09-01), Isner
patent: 6130071 (2000-10-01), Alitalo et al.
patent: 6221839 (2001-04-01), Alitalo et al.
patent: 6245530 (2001-06-01), Alitalo et al.
patent: 6361946 (2002-03-01), Alitalo et al.
patent: 6403088 (2002-06-01), Alitalo et al.
patent: 6451764 (2002-09-01), Lee et al.
patent: 6608182 (2003-08-01), Rosen et al.
patent: 6645933 (2003-11-01), Alitalo et al.
patent: 6734285 (2004-05-01), Hu et al.
patent: 6884879 (2005-04-01), Baca et al.
patent: 7109308 (2006-09-01), Rosen et al.
patent: 7115392 (2006-10-01), Rosen et al.
patent: 7153827 (2006-12-01), Hu et al.
patent: 7153942 (2006-12-01), Hu et al.
patent: 7186688 (2007-03-01), Hu et al.
patent: 7208582 (2007-04-01), Rosen et al.
patent: 7223724 (2007-05-01), Alderson et al.
patent: 7227005 (2007-06-01), Hu et al.
patent: 7273751 (2007-09-01), Coleman
patent: 7402312 (2008-07-01), Rosen et al.
patent: 7439333 (2008-10-01), Hu et al.
patent: 7498417 (2009-03-01), Hu et al.
patent: 7524501 (2009-04-01), Alderson et al.
patent: 2003/0215921 (2003-11-01), Coleman
patent: 2004/0214286 (2004-10-01), Hu et al.
patent: 2005/0059117 (2005-03-01), Rosen et al.
patent: 2005/0176103 (2005-08-01), Hu et al.
patent: 2005/0181979 (2005-08-01), Alderson et al.
patent: 2005/0192429 (2005-09-01), Rosen et al.
patent: 2005/0232921 (2005-10-01), Rosen et al.
patent: 2005/0287143 (2005-12-01), Rosen et al.
patent: 2006/0014252 (2006-01-01), Lyman
patent: 2006/0025331 (2006-02-01), Hu et al.
patent: 2006/0057117 (2006-03-01), Coleman
patent: 2008/0286288 (2008-11-01), Rosen et al.
patent: 710696 (1999-09-01), None
patent: 0186084 (1986-07-01), None
patent: 0399816 (1990-11-01), None
patent: 0476983 (1992-03-01), None
patent: 0506477 (1992-09-01), None
patent: 64-38100 (1989-02-01), None
patent: 2-117698 (1990-05-01), None
patent: WO 91/02058 (1991-02-01), None
patent: WO 92/14748 (1992-09-01), None
patent: WO 94/11506 (1994-05-01), None
patent: WO 95/19985 (1995-07-01), None
patent: WO 95/24414 (1995-09-01), None
patent: WO 95/24473 (1995-12-01), None
patent: WO 96/05856 (1996-02-01), None
patent: WO 96/39515 (1996-12-01), None
patent: WO 97/00271 (1997-01-01), None
patent: WO 97/05250 (1997-02-01), None
patent: WO 97/08320 (1997-03-01), None
patent: WO 97/09427 (1997-03-01), None
patent: WO 97/17442 (1997-05-01), None
patent: WO 97/19694 (1997-06-01), None
patent: WO 98/06844 (1998-02-01), None
patent: WO 98/07832 (1998-02-01), None
patent: WO 98/24811 (1998-06-01), None
patent: WO 98/33917 (1998-06-01), None
patent: WO 98/39035 (1998-09-01), None
patent: WO 98/49300 (1998-11-01), None
patent: WO 98/55619 (1998-12-01), None
patent: WO 98/56936 (1998-12-01), None
patent: WO 99/02545 (1999-01-01), None
patent: WO 99/08522 (1999-02-01), None
patent: WO 99/20749 (1999-04-01), None
patent: WO 99/21590 (1999-05-01), None
patent: WO 99/46364 (1999-09-01), None
patent: WO 00/45835 (2000-08-01), None
patent: WO 00/73430 (2000-12-01), None
patent: WO 00/75163 (2000-12-01), None
patent: WO 01/57226 (2001-08-01), None
patent: WO 01/58956 (2001-08-01), None
patent: WO 02/11769 (2002-02-01), None
patent: WO 02/083704 (2002-10-01), None
patent: WO 02/083849 (2002-10-01), None
patent: WO 02/083850 (2002-10-01), None
patent: WO 03/097660 (2003-11-01), None
patent: 9-403464 (1996-01-01), None
Zhu et al, Investigational New Drugs 17: 195-212, 1999.
Brown et al, J Immunol. 156(9):3285-3291, May 1996.
Vajdos et al, J Mol Biol 320(2):415-28, Jul. 5, 2002.
U.S. Appl. No. 11/980,495, inventors Rosen et al., filed Oct. 31, 2007 (Not Published).
Achen et al., “Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor-2 (Flk1) and VEGF receptor 3 (Flt4),”Proc. Natl. Acad. Sci.(USA) 95:548-553, National Academy of Sciences (Jan. 1998).
Alderson et al., “Vascular endothelial cell growth factor (VEGF)-2 enhances the development of rat photoreceptor cells in vitro,”Keystone Symposia, Ocular Cell and Molec. Bio. 202 (1999).
Altshuler et al., “Taurine promotes the differentiation of a vertebrate retinal cell type in vitro,”Development 119:1317-1328, Company of Biologists Limited (Dec. 1993).
Andersson et al., “Assignment of interchain disulfide bonds in platelet-derived growth factor (PDGF) as evidence for agonist activity of monomeric PDGF,”J. Bio. Chem. 267:11260-11266, American Society for Biochemistry and Molecular Biology (1992).
Andersson, W.F. “Human gene therapy,”Science 256:808-813, American Association for the Advancement of Science (1992).
Aprelikova et al., “FLT4, a novel class III receptor tyrosine kinase in chromosome 5q33-qter,”Cancer Res. 52:746-748, American Association for Cancer Research (1992).
Bell et al., “Human epidermal growth factor precursor: cDNA sequence, expression in vitro and gene organization,”Nucl. Acids Res. 14:8427-8446, Oxford University Press (1986).
Bellomo et al., “Mice Lacking the Vascular Endothelial Growth Factor-B Gene (Vegfb) Have Smaller Hearts, Dysfunctional Coronary Vasculature, and Impaired Recovery From Cardiac Ishemia,”Circ. Research 86:e29-e35, Lippincott, Williams & Wilkins (Feb. 2000).
Berse et al., “Vascular permeability factor (vacular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors,”Mol. Biol. Cell. 3:211-220, American Society for Cell Biology (1992).
Betsholtz et al., “cDNA sequence and chromosomal localization of human platelet-derived growth factor A-chain and its expression in tumor cell lines,”Nature 320:695-699, Macmillan Publishers (1986).
Bocker-Meffert et al., “Erythropoietin and VEGF Promote Neural Outgrowth from Retinal Explants in Postnatal Rats,”Invest. Ophthalmol. Vis. Sci. 43:2021-2026, Association for Research in Vision and Ophthalmology (Jun. 2002).
Breier et al., “Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation,”Development 114:521-532 (1992).
Claffey et al., “Vascular endothelial growth factor,”J. Biol. Chem. 267:16317-16322 (1992).
Cockerill et al., “Angiogenesis: Models and Modulators,”Intl. Rev. Cytology 159:113-160 (1995).
Corson et al., “Fibrillin binds calcium and is coded by cDNAs that reveal a multidomain structure and alternatively spliced exons at the 5′ end,”Genomics 17:476-484 (Aug. 1993).
Dignam et al., “Balbiani ring 3 in chironomus tentans encodes a 185-kDa secretory protein which is synthesized throughout the fourth larval instar,”Gene88:133-140 (1990).
Eichmann et al., “Avian VEGF-C: cloning, embryonic expression pattern and stimulation of the differentiation of VEGFR2-expressing endothelial cell precursor,&#x

Affiliated with

Also associated with

Rating

Vascular endothelial growth factor 2 does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Vascular endothelial growth factor 2, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vascular endothelial growth factor 2 will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4181818